Cargando…
Drug-Coated Balloon vs. Drug-Eluting Stents for De Novo Unprotected Left Main Stem Disease: The SPARTAN-LMS Study
The objective of this study is to compare the outcomes of patients treated with drug-coated balloons (DCBs) or second-generation drug-eluting stents (DESs) for de novo unprotected left main stem (LMS) disease. Previous studies comparing the treatment of LMS disease suggest that the mortality for DES...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963161/ https://www.ncbi.nlm.nih.gov/pubmed/36826580 http://dx.doi.org/10.3390/jcdd10020084 |
_version_ | 1784896184048943104 |
---|---|
author | Gunawardena, Tharusha D. Corballis, Natasha Merinopoulos, Ioannis Wickramarachchi, Upul Reinhold, Johannes Maart, Clint Sreekumar, Sulfi Sawh, Chris Wistow, Trevor Sarev, Toomas Ryding, Alisdair Gilbert, Tim J. Clark, Allan Vassiliou, Vassilios S. Eccleshall, Simon |
author_facet | Gunawardena, Tharusha D. Corballis, Natasha Merinopoulos, Ioannis Wickramarachchi, Upul Reinhold, Johannes Maart, Clint Sreekumar, Sulfi Sawh, Chris Wistow, Trevor Sarev, Toomas Ryding, Alisdair Gilbert, Tim J. Clark, Allan Vassiliou, Vassilios S. Eccleshall, Simon |
author_sort | Gunawardena, Tharusha D. |
collection | PubMed |
description | The objective of this study is to compare the outcomes of patients treated with drug-coated balloons (DCBs) or second-generation drug-eluting stents (DESs) for de novo unprotected left main stem (LMS) disease. Previous studies comparing the treatment of LMS disease suggest that the mortality for DES PCI is not worse than CABG. There are limited data from studies investigating the treatment of de novo LMS disease with DCB angioplasty. We compared the all-cause and cardiac mortality of patients treated with paclitaxel DCB to those with second-generation DES for de novo LMS disease from July 2014 to November 2019. Data were analysed using Kaplan–Meier analyses and propensity-matched analyses. A total of 148 patients were treated with either a DCB or DES strategy. There was no significant difference in all-cause mortality in the DCB group (19.5%) compared to the DES group (15.9%) (HR 1.42 [0.61–3.32], p = 0.42). Regarding cardiac mortality, 2 (4.9%) were recorded for the DCB group and 7 (6.5%) for the DES group (HR 1.21 [0.31–4.67], p = 0.786); for target vessel myocardial infarction, there were 0 (0%) for the DCB group and 7 (6.5%) for the DES group; and for target lesion revascularisation, there were 3 (7.3%) in the DCB group and 9 (8.3%) in the DES group (HR: 0.89 [0.24–3.30]). p = 0.86. These remained not significant after propensity score matching. We found no difference in the mortality outcomes with DCB angioplasty compared to second-generation DES, with a median follow-up of 33 months. DCB can therefore be regarded as a safe option in the treatment of LMS disease in suitable patients. |
format | Online Article Text |
id | pubmed-9963161 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99631612023-02-26 Drug-Coated Balloon vs. Drug-Eluting Stents for De Novo Unprotected Left Main Stem Disease: The SPARTAN-LMS Study Gunawardena, Tharusha D. Corballis, Natasha Merinopoulos, Ioannis Wickramarachchi, Upul Reinhold, Johannes Maart, Clint Sreekumar, Sulfi Sawh, Chris Wistow, Trevor Sarev, Toomas Ryding, Alisdair Gilbert, Tim J. Clark, Allan Vassiliou, Vassilios S. Eccleshall, Simon J Cardiovasc Dev Dis Article The objective of this study is to compare the outcomes of patients treated with drug-coated balloons (DCBs) or second-generation drug-eluting stents (DESs) for de novo unprotected left main stem (LMS) disease. Previous studies comparing the treatment of LMS disease suggest that the mortality for DES PCI is not worse than CABG. There are limited data from studies investigating the treatment of de novo LMS disease with DCB angioplasty. We compared the all-cause and cardiac mortality of patients treated with paclitaxel DCB to those with second-generation DES for de novo LMS disease from July 2014 to November 2019. Data were analysed using Kaplan–Meier analyses and propensity-matched analyses. A total of 148 patients were treated with either a DCB or DES strategy. There was no significant difference in all-cause mortality in the DCB group (19.5%) compared to the DES group (15.9%) (HR 1.42 [0.61–3.32], p = 0.42). Regarding cardiac mortality, 2 (4.9%) were recorded for the DCB group and 7 (6.5%) for the DES group (HR 1.21 [0.31–4.67], p = 0.786); for target vessel myocardial infarction, there were 0 (0%) for the DCB group and 7 (6.5%) for the DES group; and for target lesion revascularisation, there were 3 (7.3%) in the DCB group and 9 (8.3%) in the DES group (HR: 0.89 [0.24–3.30]). p = 0.86. These remained not significant after propensity score matching. We found no difference in the mortality outcomes with DCB angioplasty compared to second-generation DES, with a median follow-up of 33 months. DCB can therefore be regarded as a safe option in the treatment of LMS disease in suitable patients. MDPI 2023-02-16 /pmc/articles/PMC9963161/ /pubmed/36826580 http://dx.doi.org/10.3390/jcdd10020084 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gunawardena, Tharusha D. Corballis, Natasha Merinopoulos, Ioannis Wickramarachchi, Upul Reinhold, Johannes Maart, Clint Sreekumar, Sulfi Sawh, Chris Wistow, Trevor Sarev, Toomas Ryding, Alisdair Gilbert, Tim J. Clark, Allan Vassiliou, Vassilios S. Eccleshall, Simon Drug-Coated Balloon vs. Drug-Eluting Stents for De Novo Unprotected Left Main Stem Disease: The SPARTAN-LMS Study |
title | Drug-Coated Balloon vs. Drug-Eluting Stents for De Novo Unprotected Left Main Stem Disease: The SPARTAN-LMS Study |
title_full | Drug-Coated Balloon vs. Drug-Eluting Stents for De Novo Unprotected Left Main Stem Disease: The SPARTAN-LMS Study |
title_fullStr | Drug-Coated Balloon vs. Drug-Eluting Stents for De Novo Unprotected Left Main Stem Disease: The SPARTAN-LMS Study |
title_full_unstemmed | Drug-Coated Balloon vs. Drug-Eluting Stents for De Novo Unprotected Left Main Stem Disease: The SPARTAN-LMS Study |
title_short | Drug-Coated Balloon vs. Drug-Eluting Stents for De Novo Unprotected Left Main Stem Disease: The SPARTAN-LMS Study |
title_sort | drug-coated balloon vs. drug-eluting stents for de novo unprotected left main stem disease: the spartan-lms study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963161/ https://www.ncbi.nlm.nih.gov/pubmed/36826580 http://dx.doi.org/10.3390/jcdd10020084 |
work_keys_str_mv | AT gunawardenatharushad drugcoatedballoonvsdrugelutingstentsfordenovounprotectedleftmainstemdiseasethespartanlmsstudy AT corballisnatasha drugcoatedballoonvsdrugelutingstentsfordenovounprotectedleftmainstemdiseasethespartanlmsstudy AT merinopoulosioannis drugcoatedballoonvsdrugelutingstentsfordenovounprotectedleftmainstemdiseasethespartanlmsstudy AT wickramarachchiupul drugcoatedballoonvsdrugelutingstentsfordenovounprotectedleftmainstemdiseasethespartanlmsstudy AT reinholdjohannes drugcoatedballoonvsdrugelutingstentsfordenovounprotectedleftmainstemdiseasethespartanlmsstudy AT maartclint drugcoatedballoonvsdrugelutingstentsfordenovounprotectedleftmainstemdiseasethespartanlmsstudy AT sreekumarsulfi drugcoatedballoonvsdrugelutingstentsfordenovounprotectedleftmainstemdiseasethespartanlmsstudy AT sawhchris drugcoatedballoonvsdrugelutingstentsfordenovounprotectedleftmainstemdiseasethespartanlmsstudy AT wistowtrevor drugcoatedballoonvsdrugelutingstentsfordenovounprotectedleftmainstemdiseasethespartanlmsstudy AT sarevtoomas drugcoatedballoonvsdrugelutingstentsfordenovounprotectedleftmainstemdiseasethespartanlmsstudy AT rydingalisdair drugcoatedballoonvsdrugelutingstentsfordenovounprotectedleftmainstemdiseasethespartanlmsstudy AT gilberttimj drugcoatedballoonvsdrugelutingstentsfordenovounprotectedleftmainstemdiseasethespartanlmsstudy AT clarkallan drugcoatedballoonvsdrugelutingstentsfordenovounprotectedleftmainstemdiseasethespartanlmsstudy AT vassiliouvassilioss drugcoatedballoonvsdrugelutingstentsfordenovounprotectedleftmainstemdiseasethespartanlmsstudy AT eccleshallsimon drugcoatedballoonvsdrugelutingstentsfordenovounprotectedleftmainstemdiseasethespartanlmsstudy |